Otenaproxesul is under clinical development by Antibe Therapeutics and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Otenaproxesul’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Otenaproxesul overview

ATB-346 (otenaproxesul) is under development for the treatment of acute and chronic joint pain associated with osteoarthritis. It is administered orally. The drug candidate is a a non-steroidal anti-inflammatory, hydrogen sulfide releasing derivative of naproxen. Naproxen is an anti-inflammatory agent that targets COX-1 and COX-2. Naproxen carries a significant risk of serious gastrointestinal bleeding. This risk is reduced by the drug candidate by release of hydrogen sulphide. It was also under development for the treatment of colorectal cancer and melanoma.

Antibe Therapeutics overview

Antibe Therapeutics (Antibe) formerly Ontario, is a biotechnology company. It designs and develops therapies for the treatment of pain and inflammation. The company’s lead compound ATB-346, an anti-inflammatory drug, is designed against chronic pain and inflammation. It is investigating ATB-352, a non-addictive analgesic, to treat post-operative pain; and ATB-340, a GI (gastro-intestinal) safe derivative of aspirin, targeting cardiovascular diseases. Antibe also offers regenerative medical devices for oral maxillofacial surgery through its subsidiary. The company supplies its products in Canada, China, Israel, Russia and South Korea. Antibe is headquartered in Toronto, Ontario, Canada.

For a complete picture of Otenaproxesul’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.